Arousal of cancer-associated stromal fibroblasts

References

• Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316:2713 - 22; http://dx.doi.org/10.1016/j.yexcr.2010.04.032; PMID: 20451516
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432:332 - 7; http://dx.doi.org/10.1038/nature03096; PMID: 15549095
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101:887 - 907; http://dx.doi.org/10.1002/jcb.21209; PMID: 17266048
   PubMed Web of Science ®Google Scholar
• De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123:2229 - 38; http://dx.doi.org/10.1002/ijc.23925; PMID: 18777559
   PubMed Web of Science ®Google Scholar
• Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59:5002 - 11; PMID: 10519415
   PubMed Web of Science ®Google Scholar
• Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev 2009; 19:67 - 73; http://dx.doi.org/10.1016/j.gde.2009.01.003; PMID: 19211240
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457 - 61; http://dx.doi.org/10.1126/science.1171362; PMID: 19460966
   PubMed Web of Science ®Google Scholar
• Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68:918 - 26; http://dx.doi.org/10.1158/0008-5472.CAN-07-5714; PMID: 18245495
   PubMed Web of Science ®Google Scholar
• Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992; 175:139 - 46; http://dx.doi.org/10.1084/jem.175.1.139; PMID: 1309851
   PubMed Web of Science ®Google Scholar
• Kim EJ, Simeone DM. Advances in pancreatic cancer. Curr Opin Gastroenterol 2011; 27:460 - 6; http://dx.doi.org/10.1097/MOG.0b013e328349e31f; PMID: 21778878
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330:827 - 30; http://dx.doi.org/10.1126/science.1195300; PMID: 21051638
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21:418 - 29; http://dx.doi.org/10.1016/j.ccr.2012.01.007; PMID: 22439937
   PubMed Web of Science ®Google Scholar
• Brentnall TA, Lai LA, Coleman J, Bronner MP, Pan S, Chen R. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012; 7:e30219; http://dx.doi.org/10.1371/journal.pone.0030219; PMID: 22291919
   PubMedGoogle Scholar
• Goicoechea SM, Bednarski B, Stack C, Cowan DW, Volmar K, Thorne L, et al. Isoform-specific upregulation of palladin in human and murine pancreas tumors. PLoS One 2010; 5:e10347; http://dx.doi.org/10.1371/journal.pone.0010347; PMID: 20436683
   PubMedGoogle Scholar
• Chaudhary M, Gadbail AR, Vidhale G, Mankar Gadbail MP, Gondivkar SM, Gawande M, et al. Comparison of Myofibroblasts Expression in Oral Squamous Cell Carcinoma, Verrucous Carcinoma, High Risk Epithelial Dysplasia, Low Risk Epithelial Dysplasia and Normal Oral Mucosa. Head Neck Pathol 2012; 6:305 - 13; http://dx.doi.org/10.1007/s12105-012-0335-x; PMID: 22392407
   PubMedGoogle Scholar
• Nhieu JT, Brochériou I, Préaux AM, Mallat A, Cherqui D, Zafrani ES, et al. Myofibroblasts and hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 1998; 29:120 - 8; http://dx.doi.org/10.1016/S0168-8278(98)80186-4; PMID: 9696500
   PubMed Web of Science ®Google Scholar
• Goicoechea SM, Bednarski B, García-Mata R, Prentice-Dunn H, Kim HJ, Otey CA. Palladin contributes to invasive motility in human breast cancer cells. Oncogene 2009; 28:587 - 98; http://dx.doi.org/10.1038/onc.2008.408; PMID: 18978809
   PubMed Web of Science ®Google Scholar
• Parast MM, Otey CA. Characterization of palladin, a novel protein localized to stress fibers and cell adhesions. J Cell Biol 2000; 150:643 - 56; http://dx.doi.org/10.1083/jcb.150.3.643; PMID: 10931874
   PubMed Web of Science ®Google Scholar
• Goicoechea SM, Arneman D, Otey CA. The role of palladin in actin organization and cell motility. Eur J Cell Biol 2008; 87:517 - 25; http://dx.doi.org/10.1016/j.ejcb.2008.01.010; PMID: 18342394
   PubMed Web of Science ®Google Scholar
• Gupta V, Bassi DE, Simons JD, Devarajan K, Al-Saleem T, Uzzo RG, et al. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 2011; 6:e21494; http://dx.doi.org/10.1371/journal.pone.0021494; PMID: 21738681
   PubMedGoogle Scholar
• Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001; 61:1833 - 8; PMID: 11280733
   PubMed Web of Science ®Google Scholar
• Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004; 64:8585 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-04-1136; PMID: 15574765
   PubMed Web of Science ®Google Scholar
• Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007; 9:1392 - 400; http://dx.doi.org/10.1038/ncb1658; PMID: 18037882
   PubMed Web of Science ®Google Scholar
• Xu Z, Vonlaufen A, Phillips PA, Fiala-Beer E, Zhang X, Yang L, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 2010; 177:2585 - 96; http://dx.doi.org/10.2353/ajpath.2010.090899; PMID: 20934972
   PubMed Web of Science ®Google Scholar
• Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 2010; 107:21677 - 82; http://dx.doi.org/10.1073/pnas.1016234107; PMID: 21098274
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148:349 - 61; http://dx.doi.org/10.1016/j.cell.2011.11.025; PMID: 22265420
   PubMed Web of Science ®Google Scholar
• Hermanova M, Trna J, Nenutil R, Dite P, Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol 2008; 20:732 - 9; http://dx.doi.org/10.1097/MEG.0b013e3282f945fb; PMID: 18617777
   PubMed Web of Science ®Google Scholar
• Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Des 2012; 18:2404 - 15; PMID: 22372501
   PubMed Web of Science ®Google Scholar
• Onozuka H, Tsuchihara K, Esumi H. Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci 2011; 102:975 - 82; http://dx.doi.org/10.1111/j.1349-7006.2011.01880.x; PMID: 21255190
   PubMed Web of Science ®Google Scholar
• Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 2011; 102:1144 - 50; http://dx.doi.org/10.1111/j.1349-7006.2011.01912.x; PMID: 21338440
   PubMed Web of Science ®Google Scholar
• Engels B, Rowley DA, Schreiber H. Targeting stroma to treat cancers. Semin Cancer Biol 2012; 22:41 - 9; http://dx.doi.org/10.1016/j.semcancer.2011.12.008; PMID: 22212863
   PubMed Web of Science ®Google Scholar
• Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008; 14:4584 - 92; http://dx.doi.org/10.1158/1078-0432.CCR-07-5211; PMID: 18628473
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010; 101:2325 - 32; http://dx.doi.org/10.1111/j.1349-7006.2010.01695.x; PMID: 20804499
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31 - 41; http://dx.doi.org/10.1016/S0140-6736(10)62110-1; PMID: 21144578
   PubMed Web of Science ®Google Scholar
• Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 2008; 31:157 - 62; http://dx.doi.org/10.1097/COC.0b013e31815878c9; PMID: 18391600
   PubMed Web of Science ®Google Scholar
• Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010; 44:286 - 8; http://dx.doi.org/10.1097/MCG.0b013e3181cda097; PMID: 20216081
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14:4491 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-0024; PMID: 18628464
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62:1137 - 41; http://dx.doi.org/10.1080/01635581.2010.513802; PMID: 21058202
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79:391 - 7; http://dx.doi.org/10.1023/A:1024038127156; PMID: 12846423
   PubMed Web of Science ®Google Scholar
• Uomo I, Miraglia S, Pastorello M. Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets. JOP 2010; 11:199 - 202; PMID: 20442512
   PubMedGoogle Scholar
• Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76:254 - 61; http://dx.doi.org/10.1159/000205388; PMID: 19246950
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12:2172 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-05-2067; PMID: 16609031
   PubMed Web of Science ®Google Scholar
• Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). [review] Oncol Rep 2005; 13:559 - 83; PMID: 15756426
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21:4B 2895 - 900; PMID: 11712783
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15:97 - 101; http://dx.doi.org/10.1016/j.gde.2004.12.003; PMID: 15661539
   PubMed Web of Science ®Google Scholar
• Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010; 17:135 - 47; http://dx.doi.org/10.1016/j.ccr.2009.12.041; PMID: 20138012
   PubMed Web of Science ®Google Scholar
• Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005; 118:2143 - 53; http://dx.doi.org/10.1242/jcs.02334; PMID: 15855236
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Spångeus A, Välilä J, Sandström P, Borch K, Druid H, et al. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011; 13:664 - 75; PMID: 21847358
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904 - 10; http://dx.doi.org/10.1016/j.ctrv.2012.04.007; PMID: 22651903
   PubMed Web of Science ®Google Scholar
• Cox AD, Olive KP. Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer Cell 2012; 21:715 - 6; http://dx.doi.org/10.1016/j.ccr.2012.05.029; PMID: 22698396
   PubMed Web of Science ®Google Scholar